230
Participants
Start Date
July 31, 2012
Primary Completion Date
August 31, 2013
Study Completion Date
November 30, 2013
Daclatasvir
Tablets, oral, 30 mg, once daily
Simeprevir
Capsule, oral, 150 mg, once daily
Ribavirin
Tablets, oral, 500-600 mg, twice daily
Local Institution, Budapest
Local Institution, Buenos Aires
Local Institution, Budapest
Local Institution, Gyula
Local Institution, Berlin
Local Institution, Marseille
Local Institution, Hamburg
Johns Hopkins University, Lutherville
Metropolitan Research, Fairfax
Local Institution, Madrid
Local Institution, Pessac
Nashville Medical Research Institute, Nashville
Local Institution, Valencia
Indiana University, Indianapolis
Local Institution, Cologne
Local Institution, Vandœuvre-lès-Nancy
Local Institution, Frankfurt
Local Institution, Paris
Local Institution, Paris
Texas Clinical Research Institute, Llc, Arlington
Local Institution, Limoges
Local Institution, Créteil
San Francisco General Hospital, San Francisco
Kaiser Permanente Med Ctr, San Francisco
Local Institution, Buenos Aires
Local Institution, Barcelona
Lead Sponsor
Janssen Research & Development, LLC
INDUSTRY
Bristol-Myers Squibb
INDUSTRY